Skip to main content

Table 1 Baseline characteristics and 5-year LRR rates of 4841 pT1–2 N0 breast cancer patients after mastectomy

From: Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy

Variables

n (%)

5-year LRR (%)

p

Treatment era

 1999–2007

1915 (39.6)

5.5

< 0.001

 2008–2014

2926 (60.4)

2.8

Age (years)

 Median

51.1 ± 10.5

  

  ≤ 40

723 (14.9)

7.5

< 0.001

  > 40

4118 (85.1)

3.3

Tumor quadrant

 Inner

1255 (25.9)

5.3

< 0.001

 Non-inner

3486 (72.0)

3.0

 Unknown

100 (2.1)

18.9

pT stage

 T2

1954 (40.4)

5.3

0.003

 T1

2887 (59.6)

3.0

Molecular subtype

 Luminal

3150 (65.0)

2.8

< 0.001

 Her2 overexpression

501 (10.3)

5.0

 Triple-negative

1076 (22.2)

6.5

 Unknown

114 (2.4)

5.3

LVI

 Yes

184 (3.8)

8.1

0.011

 No

4631 (95.7)

4.0

 Unknown

26 (0.5)

11.6

Tumor grade

 I and II

2803 (57.9)

3.3

0.012

 III

1137 (23.5)

5.1

 Unknown

901 (18.6)

4.6

Histology

 IDC

4399 (90.9)

4.0

0.356

 ILC

141 (2.9)

1.9

 IMPC

26 (0.5)

0.0

 MBC

4 (0.1)

0.0

 Medullary carcinoma

56 (1.2)

6.0

 Other

215 (4.4)

2.4

Adjuvant chemotherapy

 Yes

3236 (66.8)

2.1

< 0.001

 No

1605 (33.2)

4.8

Endocrine therapy

 Yes

3113 (64.3)

2.8

< 0.001

 No

1682 (34.7)

6.1

 Unknown

46 (1.0)

0.0

 Median time (months)

44.7 ± 21.6

  

Anti-Her2 target therapy

 Yes

233 (4.8)

3.4

0.372

 No

4580 (94.6)

4.0

 Unknown

28 (0.6)

0.0

  1. ER Estrogen receptor, Her2 Human epidermal growth factor receptor 2, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, IMPC Invasive micropapillary carcinoma, LRR Locoregional recurrence, LVI Lymphovascular invasion, MBC Metaplastic breast carcinoma, PR Progesterone receptor